Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mexiletine
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®
Details : Under the agreement announced today, Medis will initially focus on the commercialization of NaMuscla® in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in the first phase.
Brand Name : NaMuscla
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 09, 2022
Lead Product(s) : Mexiletine
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?